Bevacizumab (Avastin; Genentech, Inc, South San Francisco, CA) is a recombinant
monoclonal antibody against vascular endothelial growth factor (VEGF) that is used to treat …

Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has
demonstrated clinical activity in colorectal, renal, breast, and lung cancers. It has been …

Background: Bevacizumab, a vascular endothelial growth factor (VEGF) monoclonal
antibody commonly used for the treatment of various cancers, is often associated with …

Background The monoclonal antibody bevacizumab effectively inhibits angiogenesis in
several types of cancers by blocking vascular endothelial growth factor. However, life …

BACKGROUND: Bevacizumab, a monoclonal antibody to vascular endothelial growth factor-
A, is approved for the treatment of various malignancies, and its hematological toxicities are …

To the Editor: The meta-analysis assessing the risk of venous thromboembolism (VTE) with
bevacizumab in cancer patients by Dr Nalluri and colleagues1 carefully reviewed 15 …

Background Bevacizumab is an antiangiogenic mAb with efficacy against several cancers,
but it is associated with risk of arterial thromboembolism (ATE). Further data are needed to …

Purpose We aimed to examine the risk factors, time of onset, incidence rates, and outcomes
of thromboembolic events induced by bevacizumab in patients with cancer using the …

Background/Aim: Bevacizumab combined with standard chemotherapeutics has become a
choice of treatment for several kinds of cancers. Hypertension, third-degree albuminuria …

3019 Background: BV (Avastin™) is a monoclonal antibody to VEGF with demonstrated
survival benefit when combined with CT in metastatic colorectal cancer (mCRC). Individual …